A Phase 4 interventional study of Shenqu Xiaoshi oral liquid and Domperidone suspension in Dyspepsia, sponsored by Ruijin Hospital. Completed at 1 site in China. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Ruijin Hospital · Phase 4, Interventional, and Treatment
With domperidone suspension as the control, the effect of shenqu xiaoshi oral liquid on functional dyspepsia in children was evaluated objectively through multi-center, randomized, double-blind and double-simulation experiment, which alleviated the clinical symptoms, restored and promoted the normal growth and development of children.
363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.
This study's enrollment of 356 is above the median of 87 across 297 interventional studies indexed under Dyspepsia.
Browse Dyspepsia studies →Ruijin Hospital is the lead sponsor of 635 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Shenqu Xiaoshi oral liquid
Drug: Domperidone suspension
Shenqu Xiaoshi oral liquid
Domperidone suspension
Total effective rate
Time frame: Treatment for two weeks
Clinical symptom scores
Time frame: Treatment for one/two week(s)
Total effective rate
Time frame: Two weeks after stopping the medication
Food intake
Food intake was measured by a scale filling by subjects or their parents. Scores range from 0 to 3. Higher score represents greater reduction in food intake and 0 means unchanged.
Time frame: Treatment for one/two week(s) and two weeks after stopping the medication
weight
Time frame: Treatment for one/two week(s) and two weeks after stopping the medication
The meal time
Time frame: Treatment for one/two week(s) and two weeks after stopping the medication
hemoglobin
Time frame: Treatment for two weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruijin Hospital